Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir/velpatasvir in liver transplant recipients with chronic hepatitis C
2016-000416-15Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir and velpatasvir in chronic hepatitis C (CHC), sponsored by Gilead Sciences. Primary endpoint: SVR12. Started Apr 2016; status: completed.
02
Drugs
sofosbuvirvelpatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-000416-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000416-15.